Evaluating effect of acute or chronic use of antihypertensives on risk of falls in older adults.
Falls are a major risk for older adults and are associated with increased morbidity and mortality. Between 0.85 and 1.5% of total health care expenditure is consumed on fall-related expenses in the United States, Europe, and Australia. 1 A number of widely prescribed medications have been shown to be significant contributors to falls and fractures. 2 While there are many risk factors for falls in older adults, none are potentially as preventable or reversible as medication use. 3 Cardiovascular medications are the most commonly used medicines among older adults 4 and have been identified as one of the main risk factors for falls in many studies. [5] [6] [7] [8] [9] [10] [11] Importantly, the prescription of medications to older adults has increased significantly over the last 2 decades. [11] [12] [13] There have been several systematic and literature reviews [14] [15] [16] [17] [18] examining the effect of different medications on falls since the meta-analysis by Leipzig et al. 18 using articles publishes between 1966 and 1996. Hartikainen et al. 14 performed a systematic review of studies published between 1996 and 2004 but did not pool the data for metaanalysis. Wiens et al. 15 examined the effect of antihypertensive medications on fractures, meta-analyzing articles published between 1996 and 2005. Woolcott et al. 16 updated Leipzig et al. 18 using articles published between April 1996 and August 2007 and assessed the impact of 9 medication classes on falls in older adults. Despite the number of studies, fundamental differences in study design have hampered meta-analysis. Zang et al. 17 combined the results of Leipzig et al. 18 and Wiens et al. 15 More recent studies have suggested that time after the initiation, change, or increase in dose of antihypertensive medication is a significant predictor of falls. 5, 6, 8, 10, 11, [19] [20] [21] [22] [23] [24] The aim of our systematic review was to update previous meta-analyses 16, 18 in light of recent research and to examine the association between falls and antihypertensive medication initiation, change, or dose increase in older adults.
METHODS

Data sources
Original research studies were collected through a systematic search of English language articles in CINAHL, Cochrane, EBM, EMBASE, and MEDLINE databases. Primary research articles published between 1 January 2007 and 1 June 2017 were eligible for inclusion. We combined the MeSH term "Therapeutic uses", which includes all indexed classes of drugs and individual agents, with the MeSH terms "Accidents, Home", and "Accidental Falls". In addition, the MeSH terms "Epidemiology" and "Pharmacoepidemiology" were incorporated into the systematic search to find studies in which drug exposure may have been the secondary objective of the research. The MeSH terms "Cardiovascular Agents" and "Antihypertensive Agents", "Diuretics", "Vasodilator Agents", "Nitrates", "Adrenergic beta-Antagonist" (BB), "Calcium Channel Blockers" (CCB), "Angiotensin-Converting Enzyme Inhibitors" (ACE-i), "Angiotensin Receptor Antagonists" (ARB), and agents acting on the "Renin-Angiotensin System" were associated with MeSH terms "Falls" or "Falling", or "Fractures". All terms were expanded to cover all headings and subheadings and find potentially appropriate and relevant studies. References of selected studies were checked for other potentially eligible studies (Figure 1 ). Based on Equator reporting guidelines, Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA-P) 25 was implemented for the review and selection process.
Study selection, inclusion, and exclusion criteria
Studies were included if they were primary research studies providing original statistical data of cohort, case-control, Figure 1 . PRISMA flowchart.
case-crossover, cross-sectional, or randomized controlled trial (RCT) design in which the association between use of antihypertensive medications and falls, injurious falls, and fractures in people older than 60 years were evaluated. Antihypertensive medications included all medication that had a primary therapeutic indication of reducing blood pressure. This was defined as medications within Anatomical Therapeutic Chemical (ATC) codes 26 C02 (antihypertensive), C03 (diuretic), C07 (BB), C08 (CCB), C09 (ACE-i, ARB, and RAS). Articles covering individual subgroups of nitrates and vasodilators (ATC codes C01, C04) have been excluded as these medication classes are not primarily indicated for hypertension. An operational definition for chronic use was conservatively set at medication therapy for at least 28 days, to account for pharmacokinetic, and pharmacodynamics of included medications. Articles covering temporal relationships between medication change or dose increase and falls were included for time-risk analysis. 5, 7, 10, 21, 23 
Data extraction
Article titles, key words, indexed terms, abstracts, and full texts were initially screened by H.R.K., with inclusion decided in consensus with C.R.S. and M.D.L. In addition, 10% of the excluded articles were randomly checked by C.R.S. to confirm that they did not meet the inclusion criteria. In order to be included in the meta-analysis or timerisk analysis, effect sizes needed to be reported as odds ratio (OR), relative risk (RR), incidence risk ratio (IRR), standard incidence ratio, or hazard ratio (HR). The adjusted effect sizes and 95% confidence intervals (CI) were used for analysis. When adjusted effect sizes were not reported, crude effect sizes were used. 20, [27] [28] [29] If the reported data did not meet these criteria or clarification was required to assess eligibility, the corresponding authors were contacted. If the articles only provided 2 × 2 tables of fall incidents and exposure, the effect sizes were calculated from the available data.
Information extracted from the compiled studies contained study type, study setting (hospital, nursing home, or community dwelling), country of study, mean age, demographic data, period of study, sample size, ATC codes, fall definition, types of medication, exposure period, type of effect size, confounders, medication duration, fall ascertainment method, temporal relationship between medication initiation, change or dose increase and fall, fall risk index, 30 and study design ( Table 1) .
The definition of a "fall" used by individual studies was compared with the definitions provided by WHO, 31 the Prevention of Falls Network Europe (ProFaNE) 32 and Kellogg's international working group. 33 Assessment of study quality, risk of bias The 9-item scale for cohort, case-control, and case-crossover studies, and the 10-item scale for cross-sectional studies from the Newcastle-Ottawa scale (NOS) 34 were used to assess study quality and risk of bias. Two RCTs, (B-PROOF), 35 and (SHEP), 36 followed cohorts 37, 38 of subjects to determine risk of falls. In addition to the quality assessment, methods of medication verification, and falls ascertainment were extracted from each article.
Data synthesis and analysis
Meta-analyses were performed on 6 medication classes, categorized by their ATC codes. 26 If an ATC code, name or class of medication were not reported in the study, the effect sizes were included in the non-class-specified antihypertensive group (ATC code C). The meta-analysis was conducted in accordance with the Meta-analysis Of Observational Studies in Epidemiology Group (MOOSE) protocols. 39 Articles examining acute (<28 days) use of antihypertensives were selected for time-risk analysis. Pooled OR was obtained from OR. In one instance when relative risk was reported, the author was contacted and adjusted OR was provided via personal correspondence, pooled HR was obtained from HR and IRR. Separate meta-analyses were conducted for OR and HR, following the recommendations of Egger et al. 40 ( Figures 2 and 3 ).
Owing to heterogeneity between studies in experimental design and sampling, a random-effects model was used with inverse-variance estimate of the weights, as recommended by DerSimonian and Laird. 41, 42 Subgroup sensitivity analyses with 95% CI based on Pearson's heterogeneity Chi-square test were performed for type of study (cohort, case-control, case-crossover, cross-sectional), study setting (hospital, nursing home, or community-dwelling), and mean age of participants (≤75 years old or >75 years old) where heterogeneity was greater than 50% and statistically significant (P < 0.05) ( Table 2) . Data regarding initiation, change, or dose increase of medications were examined separately. All statistical analyses were conducted using STATA/IC version 14.2, Windows 64 bit (StataCorp, TX).
RESULTS
From 5,142 studies, 29 (N = 1,234,667 participants) met our inclusion criteria. Detailed characteristics of the 29 studies are presented in (Table 1) . Among the articles included were 16 cohort, 8, 11, 20, 24, [27] [28] [29] 37, 38, [43] [44] [45] [46] [47] [48] [49] 7 case-control, 9,21,22,50-53 5 case-crossover, 5-7,10,23 and 1 cross-sectional study. 19 Of the 16 cohort studies, 8 were prospective studies with 6 months, 20,27 1 year, 8, 28, 29, 45, 48 and 3-to 6-year follow-up periods. 24 Among studies providing a standard definition of a "fall", 5 used the WHO, 31 4 8,23,52,53 used the ProFaNE, 32 and 3 28, 37, 48 used the Kellogg definition. 33 Most of the studies adjusted their effect sizes for age, sex, and comorbidity. Only 2 studies 10,29 using OR and 3 studies using HR 20, 27, 28 presented crude effect sizes.
Twenty-six articles involving chronic antihypertensive medication use were meta-analyzed. Heterogeneity was observed in OR forest plots. There was no heterogeneity for studies examining antihypertensive medication classes C02, C03, or C07. There was heterogeneity in ATC codes C, C08 and C09. For ATC C (non-class-specific hypertensive), a significantly reduced risk of falling was noted only in studies of community-dwelling older adults (OR = 0.84, 95% CI, 0.68-0.99) and subjects 75 years of age and younger Ham et al. 37 Community 2014/32(mon)/ -2 to -3 yrs. Thorel et al. 49 Community 2014/24(mon) The Anatomical Therapeutic Chemical (ATC) Classification System. C: Non-class specified antihypertensive; C02: Antihypertensive; C03: Diuretic; C07: Beta-blocking agent; C08: Calcium channel blocker; C09: Agents acting on renin-angiotensin system (ACE-i, RAS, ARB Antihypertensive medication and falls, odds ratio meta-analysis, including prior evidence. Antihypertensive medications and falls, metaanalysis results. Odds ratios and 95% confidence intervals for each individual or pooled study effect-sizes, ATC codes: C, C02, C03, C07, C08, C09. Statistical analysis calculated by random-effect inverse-variance (REIV) model. Abbreviations: Ahy, antihypertensive; ACE-i (ACE inhibitor), angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; αB, alpha blocker; BB, beta-blocker; CCB, calcium channel blocker; CI, confidence interval; CT, cardiac therapy; CV, cardiovascular; D, diuretic; Ni, nitrate; RAS, renin-angiotensin system (RAS); Tz, thiazide. ATC code: The Anatomical Therapeutic Chemical (ATC) Classification System. C: Non-class specified antihypertensive, Cardiovascular system; C02: Antihypertensive; C03: Diuretic; C07: Beta-blocking agent; C08: Calcium channel blocker; C09: Agents acting on renin-angiotensin system (ACE-i, RAS, ARB).
(OR = 0.93, 95% CI, 0.91-0.96), leading to a reduced risk for ATC code C overall (pooled OR = 0.90, 95% CI, 0.83-0.98). For classes C08 (CCB) and C09 (ACE-i, ARB, and RAS) all effect sizes found no significant association between medications and falls.
No significant differences between the OR or HR for different populations (i.e., residents in the community, hospital, or nursing home), mean age (≤75 or >75 years), or type of study (cohort, case-control, case-crossover, or cross-sectional) were noted. Although some minor variations in the Antihypertensive medication and falls, hazard ratio meta-analysis. Antihypertensive medication and falls, meta-analysis results. Hazard ratios and 95% confidence interval (95% CI) for each individual or pooled study effect-size, ATC codes: C, C02, C03, C07, C08, C09. Abbreviations: Ahy, antihypertensives; ACE-i (ACE inhibitor), angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; αB, alpha blocker; BB, beta-blocker; CCB, calcium channel blocker; CT, cardiac therapy; CV, cardiovascular; D, diuretic; Ni, nitrate; RAS, renin-angiotensin system (RAS); Tz, thiazide.
stratified OR and HR were noticed, none of these were statistically significant (Table 2) .
Only one study 11 in the meta-analysis used propensity score matching 54 to control for confounding by indication, 55, 56 while most of the studies used multivariable modelling and reported adjusted OR or HR.
Five studies 5, 7, 10, 21, 23 investigated commencement of cardiovascular medication as a risk factor for falls and were included in time-risk analysis. Four studies had case-crossover and 1 study 21 had case-control design. Studies varied in setting (community, hospital, or long-term residential facility). One of these studies 7 presented the data as IRR with the remainder providing OR as effect size. Two articles 10, 21 were included in both meta-analysis and time-risk analysis (Table 1) . Table 1 includes results for non-class-specified antihypertensive medication, diuretic, BB, CCB, and ACE-i. Figures  2 and 3 show the OR, HR, and 95% CI of each study, along with the random-effects inverse-variance pooled effect size of each class of medication. OR pooled by Leipzig et al. 18 in fixed-effects models and by Woolcott et al. 16 in Bayesian models were documented as sources of prior evidence without being included in our meta-analysis. For non-class-specific antihypertensives (ATC code C), the OR reported by Leipzig et al. 18 (OR = 1.16, 95% CI, 0.87-1.55) and Woolcott et al. 16 (OR = 1.26, 95% CI, 1.08-1.46) were significantly different (P = 0.010) to our pooled OR (OR = 0.90, 95% CI, 0.83-0.98). Our pooled effect size for BB use (OR = 0.93, 95% CI, 0.89-0.98) differed from the Bayesian estimate calculated by Woolcott et al. 16 (OR = 1.14, 95% CI, 0.97-1.33), although the difference was not statistically significant (P = 0.816).
Chronic hypertensive use
Dose and risk
Callisaya et al. 8 demonstrated that higher daily defined dose (DDD) is independently associated with falls and with more than 3 DDD, OR of falling increased from 1.17 (95% CI 0.77-1.77) to 1.56 (95% CI 1.02-2.38). Tinetti et al. 11 reported that the HR of falling increased from 2.17 (95% CI, 0.98-4.8) for moderate doses to 2.31 (95% CI, 1.01-5.29) for high doses of antihypertensives. Shimbo et al. 10 Pooled OR and HR. Stratified by population setting, type of study, and mean age of participants in OR and HR. ATC code: The Anatomical Therapeutic Chemical (ATC) classification system. C, non-class-specified antihypertensive; C02, antihypertensives; C03, diuretics; C07, betablocking agents; C08, calcium channel blockers; C09, agents acting on RAS (ACE-i, RAS, ARB). Statistical analysis: calculated by randomeffects inverse-variance model (REIV). Abbreviations: ACE-i (ACE inhibitor), angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; ED, emergency department, ED were considered as community in the sensitivity analysis as the fall has occurred in the community; HR, hazard ratio; L/N, long-term care/nursing home; OR, odds ratio; HR, hazard ratio; n, number of effect-sizes in the meta-analysis; RAS, renin-angiotensin system. a Heterogeneity was not observed in HR plot, sensitivity analysis is to provide an updated comparison view between OR and HR studies.
investigated polypharmacy
and demonstrated that increasing the number of classes of medication from 1 to 2 or more will increase the OR of falling from 1.31 (95% CI, 1.13-1.52) to 1.58 (95% CI, 1.17-2.13). Lipsitz et al. 45 reported that higher doses of CCB were associated with a lower risk of falls compared with those not taking CCB (OR = 0.44, 95% CI, 0.24-0.82). In addition, higher doses of ACE-i associated with a significantly lower risk of falls occurring outside home (OR = 0.40, 95% CI, 0.18-0.92). Low or standard ACE-i doses were associated with a significant reduction in injurious falls (OR = 0.58, 95% CI, 0.34-0.99), while high doses were associated with a nonsignificant reduction (OR = 0.53, 95% CI, 0.27-1.04) compared with those not taking ACE-i. 45 
Time and risk
Two studies 21, 23 found a highly elevated risk of falling in the first 0-24 hours (day 0) after initiation, increase of dose or change of antihypertensive medication (Figure 4 ) for nonclass-specified antihypertensives, diuretics, BB, CCB, and ACE-i/ARB. The risk of falling on diuretics remained significantly elevated until day 21, with a trend toward being significantly elevated until day 28. The risk of falling for all other antihypertensive classes decreased to nonsignificant levels from day 1 onward. From day 28 onward, no antihypertensive medication was associated with an increased risk if falling.
DISCUSSION
Our study found that the risk of falling was influenced by duration of antihypertensive treatment, being significantly elevated and highest during the first 24 hours (day 0) following medication initiation, change, or dose increase, with the odds increasing up to 36 times. 21 Chronic antihypertensive medication use (≥28 days) was not associated with an increased risk of falling in older adults. When the diuretic class (ATC code 03) was examined, the risk of falling remained significantly elevated until day 21 and nonsignificantly elevated in chronic use. Chronic BB use appeared to be associated with a significantly reduced risk of falling.
These findings suggest that a first dose effect may contribute to falls in susceptible older adults, possibly due to substantial drops in blood pressure and orthostatic hypotension. Antihypertensive medications that cause hypovolemia, bradycardia, and arterial or venous dilatation may predispose to this phenomenon. For diuretics, however, it takes longer, possibly up to 28 days, to decline to the low-risk and no-risk zone. This extended duration of risk may be due to a diuresis effect.
Our pooled OR for BB use was nonsignificantly lower than the Bayesian estimate calculated by Woolcott et al. 16 As we excluded BB use of less than 28 days from our metaanalysis, our pooled OR reflects chronic BB use more accurately than earlier meta-analyses which included both acute and chronic BB use. Also, there appeared to be a statistically significant reduction in risk of falling with chronic use of BB and non-class-specific antihypertensive use (ATC code C). This finding could be due to confounding by selective prescribing, where frail older adults (those more likely to fall) are less likely to receive chronic treatments (such as BB) than older adults who are not frail. The latter group may also be more likely to pursue and adhere to other therapies, such Figure 4 . Time-effect analysis: association of antihypertensive medication and falls. Abbreviations: ATC code, The Anatomical Therapeutic Chemical (ATC) Classification System; C, non-class specified antihypertensive; Cardiovascular system: C02, antihypertensive; C03, diuretic; C07, beta-blocking agent; C08, calcium channel blocker; C09, agents acting on renin-angiotensin system (ACE-i, RAS, ARB).
as exercise, that may reduce the risk of falls. It is also possible that BB may protect against falls in some way, although this would be difficult to evaluate outside the RCT setting. Conversely Lipsitz et al. 45 found that higher doses of ACE-i were associated with lower risk of injurious falls and CCB with lower risk of all and indoor falls. Lipsitz et al. 45 suggests that one potential mechanism that CCBs contribute to prevention of falls is an increase in cerebral blood flow and prevention of ischemic brain injury. For ACE-i, Lipsitz et al. suggests that possible improvement of skeletal muscle function. 57 Leipzig et al. 18 found that thiazide diuretics had higher OR than loop diuretics but suggested that the risk of falls had been declining over the years 1975 to 1993, possibly due to lower doses of medications being used. The subsequent meta-analysis by Woolcott et al., 19 including studies published between 1996 to 2007, found that diuretic use was associated with increased fall risk in unadjusted meta-analysis but not when adjustment was made for other risk factors for falls. Similarly, our meta-analysis found that chronic diuretic use was not associated with a significantly increased risk of falling. In our study, OR and HR were meta-analyzed separately. HR provides an estimate of falls risk at each point in time during the follow-up period and should not be meta-analyzed with OR, which estimates the risk of falls across the entire follow-up period. As risk of falling with antihypertensive medication is time-dependent, effect sizes should be calculated and reported as HR, IRR, or standard incidence ratio rather than OR or relative risk. The majority of included studies did not provide a gender-specific effect size. Studies should distinguish between chronic medication use and acute changes in medication. Moreover, it is clearly visible in HR/IRR effect sizes that there is lower heterogeneity between studies. 58, 59 The degree of heterogeneity observed in our OR plots may have been due to differences in study design, degree of adjustment for confounders, follow-up duration, and outcome variable (falls, injurious falls, or fractures). Studies that did not adjust for confounding may have overestimated the association between medications and falls. Leipzig et al. 18 suggested that heterogeneity could also be attributed to varying doses of antihypertensive medications or confounding by indication. For example, studies reporting significantly elevated risk of falling with diuretic 45 and CCB 10 involved hospital patients, where sicker or frailer patients may have been more likely to fall and receive antihypertensive therapy. Future meta-regression could be conducted to identify sources of heterogeneity. Researchers should incorporate time into their study designs (index, incident, initiation, and exposure times) and distinguish between acute and chronic medication use. A case-crossover or RCT design are more appropriate designs, 40 although the propensity score method 54 could reduce confounding by indication in future observational studies.
Strengths and limitations
By analyzing chronic antihypertensive medication use separately to acute use, our study was able to reduce study heterogeneity and examine the relationship between duration of therapy and risk of falls. We used the random-effects inverse-variance method to account for study heterogeneity and conducted separate analyses for OR and HR. 40 A limitation to our study was the inclusion of published articles only written in English.
In conclusion, there is no significant increase in risk of falls for chronic use of antihypertensive medication. The risk of falling is highest 0 to 24 hours after antihypertensive medication initiation, change, or dose increase (day 0) and remains significantly elevated between days 1 to 21 for diuretics. We recommend that health care practitioners exercise extra vigilance and initiate strategies to reduce the risk of falling in older adults prior to and for these periods.
KEY POINTS
Question Is there any association between acute (<28days) or chronic (≥28days) use of antihypertensive medications and falls in older adults (age 60 years and older)?
Findings The risk of falling is highest during acute antihypertensive use. OR was highest 0 to 24 hours after antihypertensive medication initiation, change, or dose increase (day 0). For diuretics, the OR remained significantly elevated until day 21. There was no association between chronic use of antihypertensive medications and falls in older adults. Meaning Strategies to reduce the risk of falling should be implemented prior to commencing antihypertensive medications in older adults.
